AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
glucagon-like peptide (GLP) analogues and agonists	2994	9007-92-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ogluo glucagon hydrochloride recombinant glucagen glucagon glucagonoid glukagon hyperglycemic-glycogenolytic factor glucagon hydrochloride glucagon HCl glucagon recombinant	A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Molecular weight: 3482.80 Formula: C153H225N43O49S CLOGP: LIPINSKI: 3 HAC: 92 HDO: 55 TPSA: 1538.74 ALOGS: -4.71 ROTB: 113

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ogluo
glucagon hydrochloride recombinant
glucagen
glucagon
glucagonoid
glukagon
hyperglycemic-glycogenolytic factor
glucagon hydrochloride
glucagon HCl
glucagon recombinant

A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511)

Molecular weight: 3482.80
Formula: C153H225N43O49S
CLOGP:
LIPINSKI: 3
HAC: 92
HDO: 55
TPSA: 1538.74
ALOGS: -4.71
ROTB: 113

Drug dosage:

Dose	Unit	Route
3	mg	N
1	mg	P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company
March 25, 2020	PMDA	Eli Lilly Japan K.K.
Feb. 2, 2021	EMA	XERIS PHARMACEUTICALS IRELAND LIMITED
Nov. 14, 1960	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intentional overdose	141.81	19.62	80	5120	93754	90529493
Hypoglycaemia	82.95	19.62	51	5149	69797	90553450
Vasoplegia syndrome	81.43	19.62	21	5179	2793	90620454
Toxicity to various agents	76.24	19.62	88	5112	287758	90335489
Hypotension	70.72	19.62	90	5110	325307	90297940
Shock	67.58	19.62	33	5167	28745	90594502
Cardiac arrest	64.18	19.62	51	5149	104884	90518363
Cardiogenic shock	57.28	19.62	28	5172	24440	90598807
Suicide attempt	55.66	19.62	41	5159	75358	90547889
Nasal discomfort	54.98	19.62	18	5182	5530	90617717
Bradycardia	53.95	19.62	42	5158	83805	90539442
Hypoglycaemic seizure	53.24	19.62	11	5189	549	90622698
Overdose	51.71	19.62	54	5146	157655	90465592
Necrolytic migratory erythema	48.44	19.62	6	5194	6	90623241
Pulseless electrical activity	46.60	19.62	18	5182	8914	90614333
Hypothermia	43.09	19.62	20	5180	15555	90607692
Distributive shock	41.71	19.62	13	5187	3411	90619836
Rhinalgia	41.19	19.62	12	5188	2506	90620741
Infective pulmonary exacerbation of cystic fibrosis	40.76	19.62	17	5183	10262	90612985
Non-cardiogenic pulmonary oedema	39.67	19.62	10	5190	1214	90622033
Circulatory collapse	39.62	19.62	22	5178	24882	90598365
Lactic acidosis	38.49	19.62	28	5172	50435	90572812
Pulmonary oedema	37.56	19.62	30	5170	62050	90561197
Blood glucose increased	37.42	19.62	36	5164	95210	90528037
Multiple organ dysfunction syndrome	37.09	19.62	31	5169	68305	90554942
Haemodynamic instability	35.38	19.62	16	5184	11723	90611524
Hyperglycaemia	33.79	19.62	26	5174	50944	90572303
Blood glucose decreased	32.70	19.62	19	5181	23410	90599837
Respiratory failure	32.59	19.62	37	5163	118381	90504866
Atrioventricular block first degree	30.17	19.62	13	5187	8498	90614749
Hypoxia	29.64	19.62	28	5172	72371	90550876
Electrocardiogram U wave present	28.81	19.62	5	5195	96	90623151
Encephalopathy	27.14	19.62	22	5178	46422	90576825
Diabetic retinal oedema	27.10	19.62	6	5194	416	90622831
Diabetic ketoacidosis	26.86	19.62	17	5183	24390	90598857
CSF pressure increased	26.67	19.62	5	5195	150	90623097
Metabolic acidosis	25.64	19.62	23	5177	55653	90567594
Hyperlipidaemia	25.32	19.62	16	5184	22900	90600347
Cytotoxic oedema	25.28	19.62	5	5195	200	90623047
Multiple lentigines syndrome	25.04	19.62	5	5195	210	90623037
Electrocardiogram P wave abnormal	24.64	19.62	5	5195	228	90623019
Cataract subcapsular	23.83	19.62	6	5194	725	90622522
Diabetic retinopathy	23.71	19.62	8	5192	2694	90620553
Mental status changes	23.68	19.62	20	5180	44659	90578588
Hyperdynamic left ventricle	23.48	19.62	5	5195	289	90622958
Colour blindness	22.70	19.62	5	5195	339	90622908
Electrocardiogram T wave amplitude decreased	21.85	19.62	5	5195	403	90622844
Retinal ischaemia	21.25	19.62	5	5195	455	90622792
Episcleritis	20.93	19.62	6	5194	1184	90622063
Acute kidney injury	20.56	19.62	52	5148	320335	90302912
Urine ketone body present	20.22	19.62	7	5193	2545	90620702
Blindness cortical	19.97	19.62	5	5195	590	90622657

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuritis	280.97	28.10	83	7135	6137	42607980
Pulmonary vasculitis	276	28.10	82	7136	6184	42607933
Neurological symptom	242.27	28.10	83	7135	9908	42604209
Eosinophilic granulomatosis with polyangiitis	238.02	28.10	79	7139	8559	42605558
Respiratory symptom	226.10	28.10	81	7137	11025	42603092
Total lung capacity abnormal	216.96	28.10	63	7155	4380	42609737
Pulmonary alveolar haemorrhage	210.37	28.10	83	7135	14733	42599384
Haemoptysis	208.22	28.10	117	7101	46050	42568067
Forced expiratory volume decreased	199.13	28.10	67	7151	7563	42606554
Mite allergy	183.49	28.10	57	7161	4989	42609128
Vasculitis	183.19	28.10	80	7138	18314	42595803
Mycotic allergy	181.01	28.10	56	7162	4835	42609282
Dust allergy	180.39	28.10	57	7161	5275	42608842
Conjunctivitis allergic	178.67	28.10	58	7160	5853	42608264
Antineutrophil cytoplasmic antibody positive	178.66	28.10	54	7164	4311	42609806
Obstructive airways disorder	175.43	28.10	85	7133	24674	42589443
Spirometry abnormal	174.04	28.10	55	7163	5091	42609026
Pulmonary fibrosis	163.53	28.10	83	7135	26598	42587519
Sleep disorder due to a general medical condition	161.18	28.10	72	7146	17381	42596736
Normochromic normocytic anaemia	154.61	28.10	58	7160	8973	42605144
Full blood count abnormal	140.79	28.10	78	7140	29798	42584319
Hypothyroidism	138.28	28.10	79	7139	32005	42582112
Nodule	136.19	28.10	58	7160	12476	42601641
Capillaritis	128.56	28.10	36	7182	2192	42611925
Productive cough	126.80	28.10	89	7129	51478	42562639
Lung disorder	123.18	28.10	85	7133	47838	42566279
Arteriosclerosis	122.09	28.10	60	7158	17929	42596188
Soft tissue mass	120.03	28.10	29	7189	983	42613134
Multimorbidity	117.06	28.10	28	7190	909	42613208
Arteriosclerosis coronary artery	117.02	28.10	59	7159	18618	42595499
Oesophageal perforation	109.42	28.10	28	7190	1205	42612912
Wheezing	108.53	28.10	83	7135	54698	42559419
Asthma	105.37	28.10	86	7132	62228	42551889
Loss of personal independence in daily activities	99.82	28.10	76	7142	49740	42564377
Superinfection	89.32	28.10	29	7189	2922	42611195
Hypoxia	89	28.10	82	7136	69704	42544413
Therapeutic product effect incomplete	85.93	28.10	81	7137	70858	42543259
Transplant failure	80.37	28.10	29	7189	4015	42610102
Hypoglycaemia	75.65	28.10	70	7148	59784	42554333
Lung consolidation	72.84	28.10	31	7187	6646	42607471
Inflammatory marker increased	65.95	28.10	29	7189	6727	42607390
Bradycardia	64.76	28.10	76	7142	85408	42528709
Oesophageal carcinoma	64.74	28.10	32	7186	9664	42604453
Anxiety	62.44	28.10	88	7130	118472	42495645
Immunosuppressant drug level increased	59.12	28.10	28	7190	7703	42606414
Rales	54.29	28.10	30	7188	11370	42602747
Vasoplegia syndrome	52.61	28.10	19	7199	2636	42611481
Thrombosis	50.35	28.10	60	7158	68451	42545666
Hypotension	49.60	28.10	124	7094	257507	42356610
Myocardial ischaemia	49.11	28.10	33	7185	17729	42596388
Intentional overdose	47.95	28.10	51	7167	51405	42562712
Cardiomegaly	43.62	28.10	30	7188	16736	42597381
Pain in extremity	40.67	28.10	83	7135	150521	42463596
Condition aggravated	40.55	28.10	116	7102	260638	42353479
Compartment syndrome	38.30	28.10	16	7202	3273	42610844
Fatigue	35.12	28.10	15	7203	435626	42178491
Coma scale abnormal	33.27	28.10	16	7202	4549	42609568
Labelled drug-drug interaction medication error	31.66	28.10	24	7194	15558	42598559
Pulmonary embolism	31.18	28.10	65	7153	119547	42494570
Cardiogenic shock	29.15	28.10	33	7185	35607	42578510
Hypoglycaemic unconsciousness	29.09	28.10	9	7209	775	42613342
Pulse absent	28.34	28.10	16	7202	6311	42607806

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pulmonary vasculitis	314.75	19.55	83	11662	6477	110571077
Neuritis	309.52	19.55	84	11661	7315	110570239
Eosinophilic granulomatosis with polyangiitis	261.84	19.55	80	11665	10606	110566948
Total lung capacity abnormal	248.91	19.55	64	11681	4519	110573035
Neurological symptom	247.68	19.55	84	11661	15524	110562030
Respiratory symptom	247.29	19.55	83	11662	14862	110562692
Pulmonary alveolar haemorrhage	226.71	19.55	84	11661	20066	110557488
Haemoptysis	219.59	19.55	120	11625	71234	110506320
Mite allergy	206.34	19.55	58	11687	5745	110571809
Dust allergy	204.41	19.55	58	11687	5943	110571611
Forced expiratory volume decreased	201.56	19.55	69	11676	13107	110564447
Conjunctivitis allergic	200.53	19.55	59	11686	6872	110570682
Mycotic allergy	200.35	19.55	57	11688	5897	110571657
Spirometry abnormal	200.27	19.55	56	11689	5441	110572113
Antineutrophil cytoplasmic antibody positive	200.05	19.55	55	11690	5021	110572533
Vasculitis	173.74	19.55	82	11663	35791	110541763
Intentional overdose	173.68	19.55	130	11615	132371	110445183
Obstructive airways disorder	168.44	19.55	87	11658	46062	110531492
Normochromic normocytic anaemia	167.58	19.55	60	11685	12997	110564557
Capillaritis	141.95	19.55	36	11709	2403	110575151
Hypoglycaemia	136.91	19.55	107	11638	115997	110461557
Full blood count abnormal	134.04	19.55	80	11665	55972	110521582
Arteriosclerosis coronary artery	132.72	19.55	61	11684	25057	110552497
Arteriosclerosis	130.40	19.55	60	11685	24707	110552847
Vasoplegia syndrome	130.15	19.55	40	11705	5399	110572155
Hypothyroidism	126.66	19.55	85	11660	72814	110504740
Hypoxia	124.58	19.55	106	11639	129409	110448145
Bradycardia	123.15	19.55	114	11631	155403	110422151
Sleep disorder due to a general medical condition	121.03	19.55	73	11672	52039	110525515
Productive cough	119.13	19.55	98	11647	114207	110463347
Hypotension	117.64	19.55	204	11541	523645	110053909
Soft tissue mass	116.32	19.55	28	11717	1505	110576049
Nodule	111.84	19.55	59	11686	32572	110544982
Multimorbidity	111.42	19.55	27	11718	1493	110576061
Oesophageal perforation	109.07	19.55	27	11718	1632	110575922
Pulmonary fibrosis	101.14	19.55	85	11660	101957	110475597
Cardiogenic shock	83.48	19.55	60	11685	57278	110520276
Transplant failure	80.31	19.55	28	11717	5607	110571947
Superinfection	79.69	19.55	28	11717	5735	110571819
Lung consolidation	73.30	19.55	31	11714	10445	110567109
Oesophageal carcinoma	70.45	19.55	31	11714	11493	110566061
Loss of personal independence in daily activities	63.59	19.55	79	11666	149941	110427613
Lung disorder	62.62	19.55	86	11659	179961	110397593
Cardiac arrest	62.52	19.55	90	11655	196663	110380891
Non-cardiogenic pulmonary oedema	62.28	19.55	18	11727	1966	110575588
Suicide attempt	59.92	19.55	64	11681	103330	110474224
Toxicity to various agents	58.88	19.55	146	11599	480409	110097145
Acute kidney injury	58.78	19.55	174	11571	635256	109942298
Immunosuppressant drug level increased	57.34	19.55	27	11718	11697	110565857
Thrombosis	57.29	19.55	64	11681	108598	110468956
Infective pulmonary exacerbation of cystic fibrosis	57.20	19.55	29	11716	14742	110562812
Inflammatory marker increased	54.84	19.55	28	11717	14441	110563113
Shock	53.81	19.55	45	11700	53543	110524011
Compartment syndrome	53.36	19.55	21	11724	5889	110571665
Myocardial ischaemia	50.88	19.55	33	11712	26651	110550903
Hypoglycaemic seizure	49.98	19.55	13	11732	959	110576595
Therapeutic product effect incomplete	48.53	19.55	86	11659	223719	110353835
Cardiomegaly	48.25	19.55	33	11712	29097	110548457
Asthma	44.09	19.55	88	11657	250203	110327351
Wheezing	44.08	19.55	89	11656	255141	110322413
Rales	43.30	19.55	29	11716	24710	110552844
Lactic acidosis	42.76	19.55	51	11694	92760	110484794
Coma scale abnormal	40.32	19.55	20	11725	9706	110567848
Pulmonary embolism	38.47	19.55	76	11669	214398	110363156
Anxiety	37.20	19.55	100	11645	344978	110232576
Overdose	36.23	19.55	78	11667	233716	110343838
Joint swelling	35.86	19.55	3	11742	442842	110134712
Arthralgia	34.56	19.55	20	11725	779612	109797942
Hypoglycaemic unconsciousness	33.60	19.55	10	11735	1210	110576344
Distributive shock	33.26	19.55	15	11730	5889	110571665
Pulseless electrical activity	32.63	19.55	21	11724	16736	110560818
Fatigue	31.97	19.55	50	11695	1215908	109361646
Pulse absent	29.29	19.55	17	11728	11275	110566279
Sepsis	28.61	19.55	88	11657	327258	110250296
Respiratory depression	28.31	19.55	25	11720	31976	110545578
Hypothermia	28.30	19.55	23	11722	26279	110551275
Labelled drug-drug interaction medication error	28.16	19.55	24	11721	29278	110548276
Metabolic acidosis	27.88	19.55	43	11702	99701	110477853
Drug intolerance	27.46	19.55	5	11740	406507	110171047
Infusion related reaction	27.28	19.55	4	11741	381158	110196396
Pruritus	27.08	19.55	14	11731	581546	109996008
Pain	24.37	19.55	40	11705	954915	109622639
Drug hypersensitivity	24.18	19.55	9	11736	454081	110123473
Electrocardiogram U wave present	24.07	19.55	5	11740	136	110577418
Respiratory failure	23.78	19.55	63	11682	215269	110362285
Alopecia	23.55	19.55	5	11740	364748	110212806
Diabetic retinal oedema	23.13	19.55	6	11739	438	110577116
Weight increased	22.88	19.55	8	11737	419636	110157918
Blood glucose increased	22.60	19.55	46	11699	132450	110445104
Blood glucose decreased	22.11	19.55	21	11724	29467	110548087
Rheumatoid arthritis	21.77	19.55	3	11742	299610	110277944
Hypersensitivity	21.52	19.55	8	11737	403990	110173564
Hyperdynamic left ventricle	21.42	19.55	6	11739	586	110576968
Multiple lentigines syndrome	21.10	19.55	5	11740	251	110577303
CSF pressure increased	20.82	19.55	5	11740	266	110577288
Nasopharyngitis	20.69	19.55	8	11737	394353	110183201
Dyspnoea	20.49	19.55	193	11552	1106679	109470875
Haemodynamic instability	20.48	19.55	18	11727	22870	110554684
Necrolytic migratory erythema	20.29	19.55	3	11742	9	110577545
Mental status changes	20.13	19.55	32	11713	76090	110501464
Drug level increased	19.98	19.55	25	11720	47694	110529860

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H04AA01	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PANCREATIC HORMONES GLYCOGENOLYTIC HORMONES Glycogenolytic hormones
FDA PE	N0000008635	Decreased GI Motility
FDA PE	N0000008636	Decreased GI Smooth Muscle Tone
FDA PE	N0000008652	Decreased Glycolysis
FDA PE	N0000009340	Increased Gluconeogenesis
FDA PE	N0000009345	Increased Glycogenolysis
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D006728	Hormones
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:74518	anti-obesity agent
CHEBI has role	CHEBI:76916	hyperglycemic agent
FDA EPC	N0000190852	Antihypoglycemic Agent
FDA EPC	N0000190853	Gastrointestinal Motility Inhibitor

Related Drugs by ATC class:

H04AA Glycogenolytic hormones 1 drug

dasiglucagon

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypoglycemic disorder	indication	237630007
Severe hypoglycaemia in patients with diabetes	indication	237633009
Gastrointestinal Radiography Adjunct	indication
Diabetes mellitus	contraindication	73211009	DOID:9351
Insulinoma	contraindication	302822000	DOID:3892
Glucagonoma	contraindication	302823005
Pheochromocytoma	contraindication	302835009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.12	acidic
pKa2	3.31	acidic
pKa3	3.79	acidic
pKa4	4.27	acidic
pKa5	9.35	acidic
pKa6	9.95	acidic
pKa7	11.89	acidic
pKa8	11.98	acidic
pKa9	12.35	acidic
pKa10	12.43	acidic
pKa11	12.5	acidic
pKa12	12.59	acidic
pKa13	12.81	acidic
pKa14	12.81	acidic
pKa15	12.95	acidic
pKa16	13.03	acidic
pKa17	13.17	acidic
pKa18	13.33	acidic
pKa19	13.38	acidic
pKa20	13.39	acidic
pKa21	13.41	acidic
pKa22	13.65	acidic
pKa23	13.7	acidic
pKa24	13.74	acidic
pKa25	13.89	acidic
pKa26	13.97	acidic
pKa27	11.27	Basic
pKa28	10.75	Basic
pKa29	10.29	Basic
pKa30	7.99	Basic
pKa31	5.98	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
3MG	BAQSIMI	AMPHASTAR PHARMS INC	N210134	July 24, 2019	RX	POWDER	NASAL	10213487	Feb. 16, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA IN PATIENTS WITH DIABETES
3MG	BAQSIMI	AMPHASTAR PHARMS INC	N210134	July 24, 2019	RX	POWDER	NASAL	12370241	Feb. 16, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA IN PATIENTS WITH DIABETES
0.5MG/0.1ML (0.5MG/0.1ML)	GVOKE HYPOPEN	XERIS	N212097	Sept. 10, 2019	RX	SOLUTION	SUBCUTANEOUS	11590205	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA
0.5MG/0.1ML (0.5MG/0.1ML)	GVOKE PFS	XERIS	N212097	Sept. 10, 2019	DISCN	SOLUTION	SUBCUTANEOUS	11590205	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA
0.5MG/0.1ML (0.5MG/0.1ML)	GVOKE HYPOPEN	XERIS	N212097	Sept. 10, 2019	RX	SOLUTION	SUBCUTANEOUS	9649364	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA
0.5MG/0.1ML (0.5MG/0.1ML)	GVOKE PFS	XERIS	N212097	Sept. 10, 2019	DISCN	SOLUTION	SUBCUTANEOUS	9649364	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA
1MG/0.2ML (1MG/0.2ML)	GVOKE HYPOPEN	XERIS	N212097	Sept. 10, 2019	RX	SOLUTION	SUBCUTANEOUS	11590205	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA
1MG/0.2ML (1MG/0.2ML)	GVOKE KIT	XERIS	N212097	Aug. 20, 2021	RX	SOLUTION	SUBCUTANEOUS	11590205	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA
1MG/0.2ML (1MG/0.2ML)	GVOKE PFS	XERIS	N212097	Sept. 10, 2019	RX	SOLUTION	SUBCUTANEOUS	11590205	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA
1MG/0.2ML (1MG/0.2ML)	GVOKE HYPOPEN	XERIS	N212097	Sept. 10, 2019	RX	SOLUTION	SUBCUTANEOUS	9649364	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA
1MG/0.2ML (1MG/0.2ML)	GVOKE PFS	XERIS	N212097	Sept. 10, 2019	RX	SOLUTION	SUBCUTANEOUS	9649364	April 22, 2036	TREATMENT OF SEVERE HYPOGLYCEMIA

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
1MG/VIAL	GLUCAGON	CIPLA	A218813	Sept. 15, 2025	RX	INJECTABLE	INJECTION	April 18, 2026	COMPETITIVE GENERIC THERAPY
3MG	BAQSIMI	AMPHASTAR PHARMS INC	N210134	July 24, 2019	RX	POWDER	NASAL	March 17, 2028	NEW PATIENT POPULATION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Glucagon receptor	GPCR	P47871	GLR_HUMAN	AGONIST	EC50	9	IUPHAR	CHEMBL
Glucagon-like peptide 1 receptor	GPCR	P43220	GLP1R_HUMAN	AGONIST	Ki	7	IUPHAR
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN		EC50	10.70	CHEMBL
Adenylate cyclase	Enzyme		D4A3N4_RAT ADCY3_RAT ADCY2_RAT ADCY4_RAT ADCY8_RAT ADCY6_RAT ADCY5_RAT Q8CFM9_RAT		EC50	8.23	CHEMBL
Glucagon-like peptide 1 receptor	GPCR		F8V479_MACFA		EC50	10.51	CHEMBL
Glucagon-like peptide 1 receptor	GPCR		GLP1R_MOUSE		EC50	10.36	CHEMBL
Glucagon receptor	GPCR		GLR_RAT		IC50	8.82	CHEMBL

External reference:

ID	Source
D00116	KEGG_DRUG
16941-32-5	SECONDARY_CAS_RN
19179-82-9	SECONDARY_CAS_RN
4017456	VANDF
C0017687	UMLSCUI
CHEBI:5391	CHEBI
CHEMBL5314341	ChEMBL_ID
CHEMBL5314342	ChEMBL_ID
D005934	MESH_DESCRIPTOR_UI
DB00040	DRUGBANK_ID
1136	IUPHAR_LIGAND_ID
933	INN_ID
76LA80IG2G	UNII
16132283	PUBCHEM_CID
151823	RXNORM
14121	MMSL
4785	MMSL
585	MMSL
8000	MMSL
d00593	MMSL
002065	NDDF
007100	NDDF
10712001	SNOMEDCT_US
427742003	SNOMEDCT_US
66603002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Gvoke VialDx	HUMAN PRESCRIPTION DRUG LABEL	1	0517-2901	INJECTION, SOLUTION	1 mg	INTRAVENOUS	NDA	26 sections
Baqsimi	HUMAN PRESCRIPTION DRUG LABEL	1	0548-8351	POWDER	3 mg	NASAL	NDA	29 sections
Baqsimi	HUMAN PRESCRIPTION DRUG LABEL	1	0548-8352	POWDER	3 mg	NASAL	NDA	29 sections
Glucagon	HUMAN PRESCRIPTION DRUG LABEL	1	63323-596	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 mg	INTRAVENOUS	NDA	27 sections
Glucagon	HUMAN PRESCRIPTION DRUG LABEL	1	63323-596	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 mg	INTRAVENOUS	NDA	27 sections
Gvoke HypoPen0.5 mg Auto-Injector	HUMAN PRESCRIPTION DRUG LABEL	1	72065-120	INJECTION, SOLUTION	0.50 mg	SUBCUTANEOUS	NDA	26 sections
Gvoke HypoPen1 mg Auto-Injector	HUMAN PRESCRIPTION DRUG LABEL	1	72065-121	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	26 sections
Gvoke PFS1 mg Pre-filled Syringe	HUMAN PRESCRIPTION DRUG LABEL	1	72065-131	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	26 sections
Gvoke Kit	HUMAN PRESCRIPTION DRUG LABEL	1	72065-140	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	26 sections
Baqsimi	HUMAN PRESCRIPTION DRUG LABEL	1	85766-212	POWDER	3 mg	NASAL	NDA	29 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

glucagon 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: